The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

In the years since targeted treatments for CLL were introduced, their use in the second line has increased, but chemotherapy ...

Background Studies examining the relationship between serological status (rheumatoid factor and/or anticitrullinated antibody) and rituximab treatment outcome in rheumatoid arthritis (RA) have been ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...

JAK inhibitors were found to be either marginally more effective or as effective as biologic DMARDs in reducing pain in ...

Rectal discharge may appear in the toilet after pooping or on toilet paper without the urge to have a bowel movement. This ...

A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...

病例信息患者吕*，男，33岁，主因“发现血肌酐升高3月，周身水肿半月”入院。现病史：患者入院前3月因“原发性血小板减少症”复诊时发现血肌酐升高，为106μmol/L，当时无尿量及尿色改变，无下肢水肿，无恶心、呕吐，无胸闷憋、气，无脱发、光过敏，无皮疹 ...

Multiple sclerosis is a complex and challenging condition to manage, but a wide range of therapies offers hope for patients.

Number 5: The FDA has approved Imuldosa (ustekinumab-srlf), a biosimilar referencing Stelara (ustekinumab), for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...